Triple
T4050921
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Gilead Sciences |
E84182
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object |
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
|
E409693
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: velpatasvir | Statement: [Gilead Sciences, developed, velpatasvir]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: velpatasvir Context triple: [Gilead Sciences, developed, velpatasvir]
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
E.
Visperad
Visperad is a Zoroastrian liturgical text and ceremony that expands upon the Yasna ritual with additional invocations to various divine beings.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: velpatasvir Triple: [Gilead Sciences, developed, velpatasvir]
Generated description
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: velpatasvir Target entity description: Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
E.
Visperad
Visperad is a Zoroastrian liturgical text and ceremony that expands upon the Yasna ritual with additional invocations to various divine beings.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69aed930bd5c819083e7dcc14fc44f69 |
completed | March 9, 2026, 2:29 p.m. |
| NER | Named-entity recognition | batch_69aefb8539148190990468c1429be9dd |
completed | March 9, 2026, 4:55 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69b55659256081909154569cedd1694a |
completed | March 14, 2026, 12:36 p.m. |
| NEDg | Description generation | batch_69b5572b27c48190989311cef00b5f44 |
completed | March 14, 2026, 12:40 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69b55b333ffc8190a5df8b8d7bffa77f |
completed | March 14, 2026, 12:57 p.m. |
Created at: March 9, 2026, 3:37 p.m.